Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment
10.3760/cma.j.issn.1673-422X.2013.07.016
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗肺癌的研究进展
- Author:
Beibei ZHANG
;
Zhengbo SONG
;
Yiping ZHANG
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Drug therapy;
Lung neoplasms
- From:
Journal of International Oncology
2013;40(7):526-529
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations.Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type.In basic research,EGFR-TKIs combination with chemotherapy drugs show good synergy.But in clinical research,the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.
